ClinicalTrials.gg
TerminatedNCT02412124Updated Oct 20, 2026

Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers

An interventional study of Supportive Care and Quality-of-Life Assessment in Cervical Carcinoma, Ovarian Carcinoma and Uterine Corpus Cancer, sponsored by City of Hope Medical Center. Terminated at 1 site in United States. Open to female participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Feasibility issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Enrollment
649th of 678
3 · median 71
Started
2015
with 34 others
No phase
246 of 834
51 open now
Registered
384th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 649th largest by enrollment of the 678 interventional ones that give a count, is one of 35 that started in 2015, is one of 246 with no phase, and was the 384th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 19 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This pilot clinical trial studies a peer-to-peer support program in improving quality of life outcomes in patients with gynecologic cancer and their caregivers. Peer-to-peer support and mentoring may help improve quality of life and reduce symptoms of distress in gynecologic cancer patients and their families.

Read the detailed description

PRIMARY OBJECTIVES:

I. To test the feasibility and acceptability of a Woman-to-Woman (W2W) program for patients with gynecologic cancer at City of Hope (COH). Address the following descriptive research questions: were patients, mentors, and patients' family caregivers satisfied with the timing, format, and content of the program? Did the program benefit patients, mentors, and patients' family caregivers?

OUTLINE:

Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.

After completion of study, patients are followed up at 6 and 12 months.

03

Conditions studied

  • Cervical Carcinoma
  • Ovarian Carcinoma
  • Uterine Corpus Cancer
  • Vaginal Carcinoma
  • Vulvar Carcinoma
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PATIENT PARTICIPANTS
  • Patients with newly diagnosed or recurrent gynecologic cancer (ovarian, uterine, cervical, vaginal, vulvar) actively undergoing treatment (chemotherapy, surgery, or radiation therapy) at COH (including Duarte and South Pasadena campuses)
  • English-speaking patients
  • PEER MENTORS
  • Peer mentors will be past gynecologic cancer patients not currently undergoing treatment for their cancer, and considered without evidence of disease
  • Over age 18
  • PEER MENTORS: English-speaking patients
  • This study is open to patients of all races and ethnicities

Exclusion criteria

Exclusion Criteria:

  • PEER MENTORS:
  • Major psychiatric disease
  • Currently undergoing treatment for active gynecologic cancer
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Supportive care (W2W program)

    Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.

    Procedure: Supportive Care · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • ProcedureSupportive Care

    Complete W2W mentoring program

    Also known as: Supportive Therapy, Symptom Management, Therapy, Supportive

  • OtherQuality-of-Life Assessment

    Complete the FACT-G

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Complete the W2W Patient Survey

06

What researchers measure

Primary outcomes

  1. Change in quality of life benefits for patients, as assessed by the FACT-G

    Changes from baseline will be tested using paired t-tests. Data will be summarized using descriptive statistics, including means for normally distributed continuous data, medians for non-normally distributed continuous data or proportions for categorical data. Established instruments will be scored according to standard instructions, and appropriate descriptive statistics computed. Written comments from all open ended questions analyzed using content analysis methods.

    Time frame: Baseline to up to 12 months

  2. Satisfaction of patients with the timing, content, and format of the program, as assessed by the W2W Patient Survey

    Changes from baseline will be tested using paired t-tests. Descriptive statistics on participants' satisfaction with the timing, content, and format of the intervention will be presented through summary statistics of data from the satisfaction tools. Data will be summarized using descriptive statistics, including means for normally distributed continuous data, medians for non-normally distributed continuous data or proportions for categorical data.

    Time frame: Up to 12 months

  3. Satisfaction of mentors with the timing, content, and format of the program, as assessed by the W2W Volunteer/Mentor Survey

    Descriptive statistics on participants' satisfaction with the timing, content, and format of the intervention will be presented through summary statistics of data from the satisfaction tools.

    Time frame: Up to 12 months

  4. Satisfaction of patients' family caregivers with the timing, content, and format of the program

    Changes from baseline will be tested using paired t-tests. Descriptive statistics on participants' satisfaction with the timing, content, and format of the intervention will be presented through summary statistics of data from the satisfaction tools.

    Time frame: Up to 12 months

  5. Benefits for patients' family caregivers after participating in the program, as assessed by the Modified Caregiver Strain Index

    Data will be summarized using descriptive statistics, including means for normally distributed continuous data, medians for non-normally distributed continuous data or proportions for categorical data. Established instruments will be scored according to standard instructions, and appropriate descriptive statistics computed. Written comments from all open ended questions analyzed using content analysis methods.

    Time frame: Up to 12 months

07

Study locations

1 site
  • City of Hope Medical Center
    Duarte, California 91010, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Apr 2018, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2015
First posted
Apr 8, 2015
StartActual
Jul 23, 2015
Primary completionActual
Apr 26, 2018
CompletionActual
Apr 26, 2018
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, date precision and index terms
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 3 other changes: verification date, date precision and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02412124
Responsible party
Sponsor
First posted
Apr 8, 2015
Start date
Jul 23, 2015
Primary completion
Apr 26, 2018
Completion
Apr 26, 2018
Last update
Oct 20, 2026

Study contacts

Thanh Dellinger, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion